Overview Dividends

(MNPR) Monopar Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US61023L2079

Cancer Therapeutics, Monoclonal Antibody, Radiotherapeutic, Radiodiagnostic Agent

EPS (Earnings per Share)

EPS Growth (3y CAGR): -3.68%
EPS Trend (3y Corr): -41.3%

Last SUE: -0.10σ
Qual. Beats: 0

Revenue

Revenue Growth (3y CAGR): 0.00%

Last SUE: 0.00σ
Qual. Beats: 0

Risk via 10d forecast
Volatility	175%
Value at Risk 5%th	216%
Relative Tail Risk	-24.89%

Reward TTM
Sharpe Ratio	1.85
Alpha	333.28

Character TTM
Hurst Exponent	0.541
Beta	1.530
Beta Downside	1.472

Drawdowns 3y
Max DD	92.25%
Mean DD	52.87%
Median DD	67.28%

Description: MNPR Monopar Therapeutics October 29, 2025

Monopar Therapeutics Inc. (NASDAQ: MNPR) is a U.S.-based clinical-stage biotech focused on oncology, developing oral and radiopharmaceutical candidates that target the urokinase plasminogen activator receptor (uPAR) pathway. Its lead oral candidate, ALXN1840, is in late-stage trials, while the monoclonal antibody platform MNPR-101 is being conjugated to various radioisotopes for both therapeutic (MNPR-101-Lu with actinium-225) and diagnostic (MNPR-101-Zr with zirconium-89) applications.

Key pipeline milestones include: (1) a Phase II/III study of ALXN1840 enrolling patients with advanced solid tumors; (2) ongoing Phase I/II trials of MNPR-101-Zr as a PET imaging agent to select uPAR-positive patients; and (3) preclinical validation of MNPR-101-Lu, which aims to deliver targeted alpha-particle therapy. Monopar also collaborates with NorthStar to explore radio-immuno-therapeutics for severe COVID-19, leveraging its radiochemistry expertise.

From a financial and market-environment perspective, Monopar reported $45 million of cash and cash equivalents in its latest quarter, giving it roughly a 12-month runway at current burn rates. The global radiopharmaceutical market is projected to grow at a compound annual growth rate of ~11 % through 2030, driven by increasing demand for precision oncology diagnostics and therapeutics-trends that directly benefit Monopar’s uPAR-targeted platform. For a deeper dive into MNPR’s valuation metrics and peer comparison, you might find ValueRay’s analyst toolkit useful.

MNPR Stock Overview

Market Cap in USD	555m
Sub-Industry	Biotechnology
IPO / Inception	2019-12-19
Return 12m vs S&P 500	291%
Analyst Rating	4.20 of 5

MNPR Dividends

Currently no dividends paid

MNPR Growth Ratios

Metric	Value
CAGR 3y	87.07%
CAGR/Max DD Calmar Ratio	0.94
CAGR/Mean DD Pain Ratio	1.65
Current Volume	91k
Average Volume	152.9k

Piotroski VR‑10 (Strict, 0-10) 0.0

error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM)

FCFTA -0.08 (>2.0%) and ΔFCFTA 90.55pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)

CFO/TA -0.08 (>3.0%) and CFO -10.8m > Net Income -19.4m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 56.10 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (7.12m) change vs 12m ago 102.4% (target <= -2.0% for YES)

error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)

Asset Turnover 0.0% (prev 0.0%; Δ 0.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -2.65 (EBITDA TTM -20.0m / Interest Expense TTM -11.8m) >= 6 (WARN >= 3)

Altman Z'' -31.79

(A) 0.98 = (Total Current Assets 144.1m - Total Current Liabilities 2.57m) / Total Assets 144.2m

(B) -0.58 = Retained Earnings (Balance) -84.3m / Total Assets 144.2m

(D) -31.93 = Book Value of Equity -84.3m / Total Liabilities 2.64m

Total Rating: -31.79 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 26.62

1. Piotroski 0.0pt

2. FCF Yield -2.63%

3. FCF Margin data missing

4. Debt/Equity 0.00

5. Debt/Ebitda 6.37

6. ROIC - WACC (= -44.31)%

7. RoE -25.72%

8. Revenue Trend data missing

9. EPS Trend -41.31%

What is the price of MNPR shares?

As of November 21, 2025, the stock is trading at USD 83.00 with a total of 91,042 shares traded.
Over the past week, the price has changed by -4.61%, over one month by +7.58%, over three months by +151.52% and over the past year by +336.84%.

Is MNPR a buy, sell or hold?

Monopar Therapeutics has received a consensus analysts rating of 4.20. Therefore, it is recommended to buy MNPR.

Strong Buy: 2
Buy: 2
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the MNPR price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	111.8	34.7%
Analysts Target Price	111.8	34.7%
ValueRay Target Price	87.4	5.3%

MNPR Fundamental Data Overview November 21, 2025

Market Cap USD = 554.7m (554.7m USD * 1.0 USD.USD)
P/B = 3.9182
Beta = 1.466
Revenue TTM = 0.0 USD
EBIT TTM = -31.3m USD
EBITDA TTM = -20.0m USD
Long Term Debt = 70.9k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 31.4k USD (from shortTermDebt, last quarter)
Debt = 102.2k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -127.6m USD (from netDebt column, last quarter)
Enterprise Value = 411.1m USD (554.7m + Debt 102.2k - CCE 143.7m)
Interest Coverage Ratio = -2.65 (Ebit TTM -31.3m / Interest Expense TTM -11.8m)
FCF Yield = -2.63% (FCF TTM -10.8m / Enterprise Value 411.1m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 21.6m) / Revenue TTM)
Tobins Q-Ratio = 2.85 (Enterprise Value 411.1m / Total Assets 144.2m)
Interest Expense / Debt = 88.51% (Interest Expense 90.5k / Debt 102.2k)
Taxrate = 21.0% (US default 21%)
NOPAT = -24.7m (EBIT -31.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 56.10 (Total Current Assets 144.1m / Total Current Liabilities 2.57m)
Debt / Equity = 0.00 (Debt 102.2k / totalStockholderEquity, last quarter 141.6m)
Debt / EBITDA = 6.37 (negative EBITDA) (Net Debt -127.6m / EBITDA -20.0m)
Debt / FCF = 11.78 (negative FCF - burning cash) (Net Debt -127.6m / FCF TTM -10.8m)
Total Stockholder Equity = 75.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -13.48% (Net Income -19.4m / Total Assets 144.2m)
RoE = -25.72% (Net Income TTM -19.4m / Total Stockholder Equity 75.6m)
RoCE = -41.30% (EBIT -31.3m / Capital Employed (Equity 75.6m + L.T.Debt 70.9k))
RoIC = -32.66% (negative operating profit) (NOPAT -24.7m / Invested Capital 75.6m)
WACC = 11.65% (E(554.7m)/V(554.8m) * Re(11.65%) + (debt cost/tax rate unavailable))
Discount Rate = 11.65% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -30.86%
Fair Price DCF = unknown (Cash Flow -10.8m)
EPS Correlation: -41.31 | EPS CAGR: -3.68% | SUE: -0.10 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0

Additional Sources for MNPR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle